Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Buscopan Single and Multiple Rising Doses in Healthy Males
NCT02261077Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2007
- Primary completion
- Jul 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of hyoscine butylbromide (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum measured concentration of analyte in plasma up to 104 hours, Area under the concentration-time curve from 0 extrapolated to infinity up to 104 hours and 1 more. Started May 2007; status: completed.
02
Drugs
hyoscine butylbromide
Beyond the preview
Go deeper on NCT02261077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261077.